50343-02-7

Basic information

• Product Name: 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE
• Synonyms: 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE;3-BROMO-2-HYDROXY-5-METHOXYBENZENECARBALDEHYDE;AKOS BB-6949;ASISCHEM D29261
• CAS NO: 50343-02-7
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Mol File: 50343-02-7.mol
• Article Data: 13

Chemical Properties

• Melting Point: 108-110°C
• Boiling Point: 272.9°C at 760 mmHg
• Flash Point: 118.9°C
• Appearance: /
• Density: 1.653g/cm³
• Vapor Pressure: 0.00354mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE(50343-02-7)
• EPA Substance Registry System: 3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE(50343-02-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 50343-02-7(Hazardous Substances Data)

Usage

General Description

3-BROMO-2-HYDROXY-5-METHOXYBENZALDEHYDE is a chemical compound with the molecular formula C8H7BrO3. It is a white to off-white crystalline powder with a melting point of 146-148°C. This chemical is commonly used in organic synthesis as an intermediate for the preparation of pharmaceuticals, dyes, and other organic compounds. Its properties make it a versatile building block for the production of various substances. Additionally, it is also used in the development of new materials and as a reagent in chemical research. As a benzaldehyde derivative, this compound has potential applications in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C8H7BrO3/c1-12-6-2-5(4-10)8(11)7(9)3-6/h2-4,11H,1H3

Upstream product

• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 7726-95-6 bromine 
• 127-09-3 sodium acetate 
• 64-19-7 acetic acid 
• 5446-02-6 4-methoxymethylsalicylate 
• 2612-02-4 5-methoxysalicylic acid 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 68216-65-9 3-bromo-2,5-dimethoxybenzaldehyde 
• 1194-98-5 2,5-Dihydroxybenzaldehyde 

Relevant articles and documents

NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES

Disclosed are compounds having formula (I) or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6, and Effector are each as defined in the specification; compositions thereof; uses thereof; and methods of use thereof.

LABELLED COUMARIN DERIVATIVES

The present invention relates to compounds having selective binding for MAO-B as compared with MAO-A. The invention also provides radioactive versions of these compounds, and precursor compounds for the synthesis of these radioactive compounds. The radioactive compounds of the invention can find use for in vivo imaging applications.

A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells

Constitutive activation of the PI3K/mTOR signaling pathway contributes to carcinogenesis and metastasis in most, if not all, breast cancers. From a chromene backbone reported to inhibit class I PI3K catalytic subunits, several rounds of chemical syntheses led to the generation of a new collection of chromologues that showed enhanced ability to kill PI3K-addicted cancer cells and to inhibit Akt phosphorylation at serine 473, a hallmark of PI3K/mTOR activation. This initial screen uncovered a chromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines. Strikingly, DHM25 was shown to be a selective and covalent inhibitor of mTOR using biochemical and cellular analyses, modeling, and a large panel of kinase activity assays spanning the human kinome (243 kinases). Finally, in vivo, this novel drug was an efficient inhibitor of growth and metastasis of triple-negative breast cancer cells, paving the way for its clinical application in oncology. (Figure Presented).